Finally, although not the main focus of our review, it is also important to mention targeted therapy with BRAF inhibitors (BRAFi) in combination with MEK inhibitors (MEKi) as treatment option in BRAFV600-mutant MM patients, either as first-line or second-line therapy [11]. Here, BRAF is linked to Miyoshi myopathy.